Trials / Completed
CompletedNCT00693524
Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX
An Open, Randomized, Multicentre Clinical Study to Compare the Safety and Efficacy of a Combination of Sequential Therapy of Tacrolimus (FK506) With Monoclonal Anti-IL2R Antibodies and Mycophenolate Mofetil Versus Tacrolimus (FK506) With Steroids in Liver Allograft Transplantation
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 94 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study to evaluate the benefits and any risks of the delayed administration of tacrolimus in a combined regimen of mycophenolate mofetil and monoclonal anti-IL2R antibodies (daclizumab), in comparison with a standard steroid + tacrolimus double drug regimen
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tacrolimus | oral |
| DRUG | Anti-IL2R AB | i.v. |
| DRUG | Mycophenolate mofetil | oral |
| DRUG | prednisone | oral |
Timeline
- Start date
- 2002-11-01
- Primary completion
- 2004-03-01
- Completion
- 2004-03-01
- First posted
- 2008-06-09
- Last updated
- 2014-08-26
Locations
8 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT00693524. Inclusion in this directory is not an endorsement.